In addition, genetic, transcriptomic, and clinical evidence implicate further TNF/TNFR family members in IMIDs, driving drug development efforts that seek to remedy SLE/RA, AD, and IBD by blocking aberrant signaling involving CD40/CD40L, OX40/OX40L, and TL1A, respectively. The gene discussed is CD40; the disease is systemic lupus erythematosus.